肝胆相照论坛

标题: AASLD2019[90]组合疗法与CAPSID异位症 调节剂和干扰素α促进初生 [打印本页]

作者: StephenW    时间: 2019-10-24 13:52     标题: AASLD2019[90]组合疗法与CAPSID异位症 调节剂和干扰素α促进初生

COMBINATION THERAPY WITH CAPSID ALLOSTERIC
MODULATOR AND INTERFERON ALPHA PROMOTES INNATE
IMMUNE RESPONSE IN HBV-INFECTED HEPATOCYTES
Keisuke Fukutomi1, Hayato Hikita1, Tasuku Nakabori1,
Akiyoshi Shimoda1, Makoto Fukuoka1, Kazuhiro Murai1,
Takuo Yamai1, Ryoko Yamada1, Takahiro Kodama1, Ryotaro
Sakamori1, Hiroshi Suemizu2, Tomohide Tatsumi1 and
Tetsuo Takehara1, (1)Department of Gastroenterology and
Hepatology, Osaka University Graduate School of Medicine,
(2)Department of Laboratory Animal Research, Central
Institute for Experimental Animals
Background: Hepatitis B virus (HBV) avoids host intracellular
innate immune systems. It is reported that HBV pregenomic
RNA (pgRNA) can be recognized by RIG-I like receptors
(RLRs), which induce interferon (IFN) response in hepatocytes
Capsid allosteric modulators (CAMs) inhibit encapsidation
of pgRNA and the effect of CAMs on host innate immunity
remains unclear In this study, we investigated the effect of
CAM treatment on intracellular innate immune response
in HBV-infected hepatocytes. Methods: HepG2-hNTCP
cells, primary human hepatocytes (PHHs) and human liver
chimeric TK-NOG mice were infected with HBV derived from
HepAD38 7 cells or patient’s serum and treated with CAM
(Bay41-4109) alone or in combination with IFNα. Changes of
intracellular HBV core protein and cytoplasmic pgRNA levels,
gene expression levels of RLRs-mediated innate immune
signaling (i e RIG-I, MDA5, IRF3/7, IFNs and ISGs) and
antiviral effects were analyzed Results: Intracellular HBV core
protein levels decreased after CAM treatment To investigate
changes of cytoplasmic pgRNA levels by CAM treatment,
cytoplasmic and intracapsid RNA were extracted from HBVinfected
HepG2-hNTCP cells after CAM treatment RT qPCR
showed pgRNA levels increased in cytoplasm but decreased
in capsid, suggesting that extracapsid pgRNA accumulates
in cytoplasm Next, we investigated gene expression levels
of RLRs-mediated innate immune signaling in HBV-infected
PHHs under CAM treatment Gene expression levels of
intracellular immunity did not change with CAM monotherapy
On the other hand, IFNα upregulated gene expressions of
part of the innate immune signaling in HBV-infected PHHs
and CAM treatment enhanced the IFN-induced upregulation
of gene expressions Combination therapy with CAM and
IFNα significantly decreased HBsAg and HBeAg levels in
the supernatant and intracellular HBV DNA levels of HBVinfected
PHHs compared with CAM or IFNα monotherapy.
Finally, intrahepatic gene expression levels were analyzed
after HBV-infected human liver chimeric mice were treated
with CAM and/or IFNα for two weeks. CAM monotherapy
did not change gene expression levels of RLRs-mediated
innate immune signaling On the other hand, CAM treatment
in combination with IFNα upregulated gene expression levels
of RIG-I, MDA5 and other ISGs more strongly than IFNα
monotherapy Conclusion: Combination therapy with CAM
and IFNα activates innate immune response in HBV-infected
hepatocytes and could be a new therapeutic strategy against
HBV.

作者: StephenW    时间: 2019-10-24 13:52

组合疗法与CAPSID异位症
调节剂和干扰素α促进初生
乙肝病毒感染的肝细胞的免疫反应
福寿圭介1,Hay人ato人1,中b Tasuku 1,
下田明义1,福冈诚1,村井和宏1,
山井拓夫1,山田凉子1,高田孝弘1,太太郎
Sakamori1,Suemizu Hiroshi2,Tomohide Tatsumi1和
竹原哲夫(1)消化内科
大阪大学大学院医学系研究科
(2)中部实验动物研究所
实验动物研究所
背景:乙型肝炎病毒(HBV)避免宿主进入细胞内
先天免疫系统。据悉,HBV基因组
RIG-I类受体可以识别RNA(pgRNA)
(RLRs),在肝细胞中诱导干扰素(IFN)反应
衣壳变构调节剂(CAMs)抑制衣壳化
pgRNA的表达及CAMs对宿主固有免疫的影响
尚不清楚在这项研究中,我们调查了
CAM治疗细胞内固有免疫反应
在乙肝病毒感染的肝细胞中。方法:HepG2-hNTCP
细胞,人类原代肝细胞(PHH)和人类肝脏
嵌合的TK-NOG小鼠被HBV感染
HepAD38 7细胞或患者血清并接受CAM处理
(Bay41-4109)单独或与IFNα组合使用。变化
细胞内HBV核心蛋白和细胞质pgRNA水平,
RLRs介导的先天免疫的基因表达水平
信号(即RIG-1,MDA5,IRF3 / 7,IFN和ISG)和
分析抗病毒作用结果:细胞内HBV核心
CAM治疗后蛋白质水平下降调查
CAM处理改变细胞质pgRNA的水平,
从HBV感染的细胞中提取细胞质和衣壳内RNA。
CAM处理RT qPCR后的HepG2-hNTCP细胞
显示pgRNA水平在细胞质中上升但下降
在衣壳中,提示衣壳外pgRNA积累
在细胞质中接下来,我们研究了基因表达水平
RLRs介导的HBV感染的先天免疫信号转导
CAM处理下的PHHs基因表达水平
CAM单药治疗不会改变细胞内免疫力
另一方面,IFNα上调了
感染乙肝病毒的先天性免疫信号的一部分
和CAM治疗可增强IFN诱导的上调
基因表达联合CAM和联合疗法的研究
IFNα显着降低了HBsAg和HBeAg水平
感染HBV的上清液和细胞内HBV DNA水平
PHHs与CAM或IFNα单药治疗相比。
最后,分析了肝内基因表达水平
治疗乙肝病毒感染的人肝嵌合体小鼠后
用CAM和/或IFNα治疗两周。 CAM单药治疗
不会改变RLR介导的基因表达水平
另一方面,先天性免疫信号传导
结合IFNα上调基因表达水平
I,MDA5和其他ISG的干扰比IFNα更强
结论:CAM联合治疗
和IFNα激活HBV感染的先天免疫反应
肝细胞,可能是一种新的治疗策略
乙肝病毒。
作者: 小牡丹    时间: 2019-10-24 17:26

可能大概差不多也许估计,望梅止渴没有意义。




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5